secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProPhase Labs, Inc. (PRPH)
CIK:        0000868278
Form:       8-K
Filed at:   2024-03-15T23:59:59+00:00
Accession:  0001493152-24-010013
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProPhase Labs reports FY 2023 net loss of $16.8M; revenue down 63% to $45.2M
----------------------------------------------------------------------------

- Net loss of $16.8M ($0.98 per share) vs. net income of $18.5M ($1.17 per share) in FY 2022.
- Revenue fell 63% to $45.2M due to COVID-19 testing decline; diagnostic services revenue dropped $83.5M.
- Nebula Genomics signed international B2B deal with MenaDNA; potential $10-20M annual revenue from another agreement.
- Pharmaloz capacity guidance raised to $45M run-rate by Q3 2024, then $80-100M by H1 2025; existing customers accepted 15.2% price increase.
- BE-Smart esophageal cancer test on track for H2 2024 commercialization; Equivir trial interim results showed 68% of respiratory incidents in placebo group.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/868278/000149315224010013/0001493152-24-010013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/868278/000149315224010013/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-010013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer